Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Compagnie Industrielle de la Matière Végétale (CIMV) is a French industrial biotechnology company specialized in the biorefining of plant matter into high-value bio-based components. The company has developed a proprietary organosolv process that separates non-food lignocellulosic biomass, such as agricultural residues and wood, into cellulose, pentose sugars, and a unique form of lignin called Biolignin. These products serve as renewable, high-purity alternatives to petroleum-based chemicals for the pharmaceutical, cosmetic, and specialty chemical industries. Biolignin, in particular, is noted for its high antioxidant properties and chemical reactivity, making it suitable for health and nutrition applications. CIMV focuses on licensing its technology and operating pilot facilities to support the transition to a sustainable bio-economy.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on CIMV.